Merck & Company, Inc.$128.84JNJ · NYSE
The supplied consensus is Buy across all 22 analysts, with a mean price target of $278 versus the week’s $254.93 close. No consensus low or high target is provided, so the target cluster and full spread cannot be established. The evidence does not identify the most bullish or least bullish analyst, any named firm’s revision during the past week, or a direction for aggregate revisions. External snippets show materially different forecast figures—Zacks cites a $169.41 average from 22 analysts, Tickernerd a $210.02 median from 32 analysts, StockAnalysis $233.42, Public $259.26, and MarketBeat $266.83—but they do not provide comparable dates or analyst-level attribution. Consequently, the substantive disagreement behind the spread cannot be isolated from the supplied evidence.
